Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Summary not available.
GRAIL, LLC announced encouraging results from its PATHFINDER study on multi-cancer early detection (MCED) using a blood test. Conducted on 6,662 participants aged 50 and older, the study showed that MCED screening more than doubled cancer detection rates compared to standard methods, identifying many cancers without established screening tests. Notably, 71% of detected cancers were of types with no routine screening available, and 48% were early-stage. The test's accuracy reached 97.1% for signal origin prediction, demonstrating its potential to enhance early cancer detection.
GRAIL announced the final results from its PATHFINDER study, focusing on the Galleri multi-cancer early detection (MCED) blood test, to be presented at the ESMO Congress 2022 in Paris on September 11. The study involved 6,662 participants aged 50 and older, emphasizing the need for enhanced cancer screening. Results will highlight participant satisfaction, adherence to screening, and anxiety levels. GRAIL aims to revolutionize cancer detection by identifying multiple cancer types early, significantly improving survival rates.
Illumina (NASDAQ:ILMN) has announced a live webcast of the Innovation Roadmap session at the Illumina Genomics Forum, hosted by CEO Francis deSouza and CTO Alex Aravanis on September 29, 2022. The session is scheduled from 9:00-10:00 AM PT and will be followed by a conference call at 11:30 AM PT, where executives will discuss the roadmap and address inquiries. Investors can access the live webcast via the Investor Info section of Illumina's website. A replay of the call will be available for 30 days following the event.
Illumina (NASDAQ: ILMN) has released the full agenda for its inaugural Illumina Genomics Forum, scheduled for September 28 – October 1 in San Diego. Over 70 speakers from various fields, including former President Barack Obama and Bill Gates, will contribute to discussions on genomic health care and innovation. Key topics include personalized patient diagnosis, whole-genome sequencing, and improving healthcare outcomes. The forum aims to address significant challenges in health care and promote equitable access to genomic health.
Illumina (NASDAQ:ILMN) faces a setback as the European Commission prohibits its acquisition of GRAIL, despite prior support from the US Federal Trade Commission. The company plans to appeal this decision, asserting that the merger would enhance access to GRAIL's early cancer detection test, Galleri. Illumina claims the combined entity could save tens of thousands of lives and billions in healthcare costs in the EU. Additionally, the company is reviewing strategic alternatives for GRAIL amid the ongoing regulatory challenges.
Illumina, Inc. (NASDAQ:ILMN) achieved a significant victory with a favorable ruling from the Administrative Law Judge in the FTC's challenge to its acquisition of GRAIL. The ALJ's decision dismissed the FTC's claims that the acquisition would harm competition in the multi-cancer early detection (MCED) market. The merger aims to enhance the accessibility of GRAIL's Galleri test, which is crucial for early cancer detection. Illumina's CEO emphasized this integration as a key step toward making life-saving diagnostics affordable for everyone.
Illumina (NASDAQ: ILMN) has opened its first manufacturing facility in Shanghai, China, aimed at enhancing local production of gene sequencing instruments and consumables. This site is expected to serve increasing demand in the Chinese market and become Illumina's third-largest global production operation. The facility will initially produce 16 sequencing reagents for clinical use, with full localization projected within five years. This investment underscores Illumina's commitment to China's life sciences sector and aims to increase efficiency in its global supply chain.
Illumina (NASDAQ: ILMN) will host the inaugural Illumina Genomics Forum (IGF) from September 28 to October 1 in San Diego. The event features Chris Evert, who will discuss her personal battle with ovarian cancer and the role of genomics in early detection and treatment. Notable speakers include former President Barack Obama and Bill Gates. Key themes will explore how genomic technology is transforming patient care and enhancing health outcomes. The IGF aims to address pivotal issues in cancer treatment and improve accessibility to genomic health care.
Illumina will feature Anne Wojcicki, CEO of 23andMe, at its inaugural Illumina Genomics Forum in San Diego from September 28 to October 1, 2022. Wojcicki's session, 'Disruption Ahead,' will focus on empowering consumers in health care through genomics. She will discuss her experience in disrupting traditional health care and the acquisition of Lemonaid Health for enhanced individualized primary care. The forum will also include talks by former President Obama and Bill Gates, highlighting equitable health care and the potential of genomics in improving global health.
FAQ
What is the current stock price of Illumina (ILMN)?
What is the market cap of Illumina (ILMN)?
